BUSINESSSEMAFOR
AstraZeneca could be Britain’s next loss
AstraZeneca's potential merger with Bristol Myers Squibb could shift more of its revenue away from the UK and Europe, possibly leading to a New York relisting. US regulatory demands might require commitments to US research, manufacturing, and employment, further distancing the company from the UK. Recent trends show UK-based firms increasingly relisting in New York or being acquired by US rivals.
Mentioned
Related Signal
Adjacent reporting
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
- AstraZeneca stock sinks on reports of merger talks with Bristol Myers Squibb
- AstraZeneca said to have explored Bristol Myers merger
- AstraZeneca holds talks with Bristol Myers Squibb over £300bn merger
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger